"Hope" Drives Quality of Life in Patients With Brain Metastases, But, the "Hope Center" Remains Elusive: An Analysis of NRG-CC003
Recommended Citation
Corn BW, Paulus R, Gondi V, Mehta MP, Fogh S, Wefel JS, Videtic GM, Sun A, Yoon H, Heinzerling JH, McGarry RC, Kundapur V, Devisetty K, Wu A, McCarron EC, Pollock J, Kanner AA, Feldman DB, Pugh SL, Kachnic LA, and Movsas B. "Hope" Drives Quality of Life in Patients With Brain Metastases, But, the "Hope Center" Remains Elusive: An Analysis of NRG-CC003. Int J Radiat Oncol Biol Phys 2025.
Document Type
Article
Publication Date
7-2-2025
Publication Title
Int J Radiat Oncol Biol Phys
Abstract
PURPOSE: NRG-CC003 randomized 393 patients with small cell lung cancer to prophylactic cranial irradiation (PCI) with or without hippocampal avoidance (HA). "Hopefulness" is a cognitive construct with 3 components: goals, pathways, and agency. Hope is measurable with validated instruments. Since hope is cognitive in nature, the existence of a "hope center" in the brain-most likely in the hippocampus-has been hypothesized. One exploratory objective of NRG-CC003 posited that if hope levels were better maintained in patients randomized to PCI + HA, then the hippocampus would be implicated in the mechanism of hopefulness.
METHODS AND MATERIALS: PCI consisted of 10 fractions of 2.5 Gy. The Adult Hope Scale (AHS) was administered at time-zero and at 6 months. Regarding patient-reported outcome measures, the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 was administered at baseline and at 3, 6-, 12-, 18- and 24-month intervals. Comparisons of AHS scores by arm were made using Wilcoxon-Mann-Whitney tests, and correlation of AHS with EORTC QLQ-C30 by Pearson correlation coefficients.
RESULTS: Approximately 95% completed the AHS at baseline and 67% filled out the questionnaire at 6 months paralleling the completion rates of the conventional tools for QOL and neurocognition. When comparing hope levels (change from baseline to 6 months) there was no significant difference (P > .05) between the 2 arms of the trial. There was a correlation for the components of hopefulness with QOL; specifically, between change in agency score and QLQ-C30 global health status (ρ = 0.27, P < .0001) as well as between change in pathways score and QLQ-C30 global health status (ρ = 0.16, P = .022).
CONCLUSIONS: It is feasible to study hopefulness in the context of prospective trials conducted within the National Clinical Trials Network. The hippocampus could not be implicated as a critical structure in a central pathway that coordinates hopefulness. For the first time, validated tools established a relationship between hope and quality of life among cancer patients.
Medical Subject Headings
Humans; Quality of Life/psychology; Brain Neoplasms/secondary/psychology/radiotherapy/prevention & control; Cranial Irradiation/psychology/methods; Lung Neoplasms/pathology/psychology; Hippocampus/radiation effects/physiology; Female; Male; Middle Aged; Hope; Small Cell Lung Carcinoma/psychology/radiotherapy/secondary; Aged; Patient Reported Outcome Measures; Cognition; Adult
PubMed ID
40614783
ePublication
ePub ahead of print
Volume
123
Issue
3
First Page
642
Last Page
652
